Detalles de la búsqueda
1.
Clinical consensus on treatments for transplant-ineligible newly diagnosed multiple myeloma: double-blinded Delphi panel.
Future Oncol
; : 1-12, 2024 May 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-38861282
2.
Daratumumab Improves Depth of Response and Progression-free Survival in Transplant-ineligible, High-risk, Newly Diagnosed Multiple Myeloma.
Oncologist
; 27(7): e589-e596, 2022 07 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-35462406
3.
Real-world patient characteristics and treatment outcomes among nontransplanted multiple myeloma patients who received Bortezomib in combination with Lenalidomide and Dexamethasone as first line of therapy in the United States.
BMC Cancer
; 22(1): 901, 2022 Aug 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-35982416
4.
Patient characteristics associated with dose modifications for VRd among newly diagnosed multiple myeloma patients.
Future Oncol
; 18(36): 3983-3991, 2022 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-36377712
5.
Real-world evidence for carfilzomib dosing intensity on overall survival and treatment progression in multiple myeloma patients.
J Oncol Pharm Pract
; 28(5): 1130-1139, 2022 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-34111994
6.
Healthcare resource utilization and costs in patients with multiple myeloma with and without skeletal-related events.
J Oncol Pharm Pract
; 26(5): 1070-1079, 2020 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-31631810
7.
The risk of febrile neutropenia and need for G-CSF primary prophylaxis with the docetaxel and cyclophosphamide regimen in early-stage breast cancer patients: a meta-analysis.
Breast Cancer Res Treat
; 153(3): 591-7, 2015 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-26337685
8.
Progression-Free Survival of Daratumumab Versus Bortezomib Triplet Combination With Lenalidomide and Dexamethasone in Transplant Ineligible Patients With Newly Diagnosed Multiple Myeloma: TAURUS Chart Review Study.
Clin Lymphoma Myeloma Leuk
; 24(1): 55-63, 2024 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37838502
9.
Survey of patients and physicians on shared decision-making in treatment selection in relapsed/refractory multiple myeloma.
Transl Behav Med
; 13(4): 255-267, 2023 04 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-36688466
10.
Health-related quality of life outcomes from the CANDOR study in patients with relapsed or refractory multiple myeloma.
Leuk Lymphoma
; 62(12): 3002-3010, 2021 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-34180331
11.
Cost-effectiveness of once weekly carfilzomib 70 mg/m2 plus dexamethasone in patients with relapsed and refractory multiple myeloma in the United States.
Expert Rev Hematol
; 13(6): 687-696, 2020 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-32249621
12.
Risk factors of psychotropic polypharmacy in the treatment of children and adolescents with psychiatric disorders.
Res Social Adm Pharm
; 15(4): 395-403, 2019 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-29929905
13.
Letter--Value-Driven Treatment Decisions: Need of the Hour for Relapsed/Refractory Multiple Myeloma.
J Manag Care Spec Pharm
; 25(9): 1027-1028, 2019 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-31456499
14.
A real-world comparative analysis of carfilzomib and other systemic multiple myeloma chemotherapies in a US community oncology setting.
Ther Adv Hematol
; 10: 2040620718816699, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-30719266
15.
Physician Care Coordination and the Use of Psychotropic Polypharmacy in the Management of Pediatric Mental Disorders.
J Manag Care Spec Pharm
; 25(1): 29-38, 2019 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-30589632
16.
Effect of Psychopharmacotherapy on Body Mass Index Among Children and Adolescents with Bipolar Disorders.
J Child Adolesc Psychopharmacol
; 27(4): 349-358, 2017 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-28422528
17.
Care Provision and Prescribing Practices of Physicians Treating Children and Adolescents With ADHD.
Psychiatr Serv
; 68(7): 681-688, 2017 Jul 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28196459
Resultados
1 -
17
de 17
1
Próxima >
>>